New Pipeline

STAGE

Screen Shot 2020-02-03 at 9.43.33 PM
Discovery/Validation
Optimize
In Vivo POC
IND Studies
Phase 1
Platform: ARM™ In combination with NK Cell Based Therapies
%
Candidate: KP1237 + NK Cell Therapy• Program: CD38/Multiple Myeloma Post Transplant

IND Submitted 4Q2019

Platform: ARM™
%
Candidate: KP1237 • Program: CD38/Darzalex® R/R Multiple Myeloma

2Q2020

%
Candidate: KP0832 • Program: PSMA/Prostate Cancer
%
Candidate: KP1406 • Program: Undisclosed
Platform: MATE™
%
Candidate: TBD • Program: CD3 /FcR Multiple Indications
Platform: SYAM™
%
Candidate: TBD • Program: PSMA/CD38